I. Pirko, MD, N. L. Kuntz, MD, M. Patterson, MD, B. M. Keegan, MD, B. G. Weinshenker, MD and M. Rodriguez, MD
From the Departments of Neurology (Drs. Pirko, Kuntz, Keegan, Weinshenker, and Rodriguez) and Immunology (Dr. Rodriguez), Mayo Clinic, Rochester, MN; and Columbia University (Dr. Patterson), New York.
Reported are three children with MS who responded dramatically to interferon-ß (IFNß) therapy.
While on immunomodulatory therapy, they developed chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) that responded to IV immunoglobulin (IVIG) administration.
These cases emphasize two interesting observations:
1) IFNß treatment did not prevent development of CIDP;
2) CIDP in the context of MS responded to IVIG, even though IVIG had no therapeutic effect on the central demyelinating disease.
© 2003 American Academy of Neurology